Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Total Current Liabilities for 7 consecutive years, with $7.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 45.08% to $7.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.4 million, a 45.08% increase, with the full-year FY2024 number at $5.0 million, down 31.71% from a year prior.
  • Total Current Liabilities was $7.4 million for Q3 2025 at Vivos Therapeutics, up from $6.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $9.3 million in Q2 2021 to a low of $4.7 million in Q1 2025.
  • A 5-year average of $7.0 million and a median of $7.2 million in 2023 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 45.08% in 2025; the steepest drop was 41.75% in 2025.
  • Vivos Therapeutics' Total Current Liabilities stood at $7.5 million in 2021, then decreased by 9.27% to $6.8 million in 2022, then grew by 6.99% to $7.3 million in 2023, then plummeted by 31.71% to $5.0 million in 2024, then surged by 49.4% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Total Current Liabilities are $7.4 million (Q3 2025), $6.4 million (Q2 2025), and $4.7 million (Q1 2025).